Did you know that out of the current 3,905 gene therapies in development in 2023, only 60 made it to clinical trials by Q3? To achieve the FDA's ambitious goal of 10-20 new cell and gene therapy approvals a year by 2025, developers and manufacturers must overcome a wide range of challenges to bring their life-changing treatments to patients. In our latest piece with Pharma Focus America, our experts Kai Lipinski, Xiaojun Liu and Jing Zhu, explore these challenges further and discuss the solutions to help overcome them.
